JW Shinyak Corp.
KKRX:0672902,385.00
KRW
+20.00
(+0.85%)
ISIN
KR7067290007
Return %
Stock
S&P 500
1Y
75.24
14.20
3Y
21.09
81.12
5Y
-22.15
68.34
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Yong-Gwan Kim
- Full Time Employees
- 173
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Gwacheon-si South Korea
- IPO Date
- Feb 11, 2003
- Website
- jw-shinyak.co.kr
- Similar Companies
- Business
- JW Shinyak Corp. is a South Korea-based pharmaceutical company primarily engaged in the development, manufacturing, marketing, and distribution of prescription pharmaceuticals, over-the-counter medications, and dermatological healthcare products. The company operates across specialized therapeutic segments with a core clinical focus on dermatology, hair loss treatments, urology, otolaryngology, anti-infectives, and general healthcare. Its primary product portfolio encompasses dermatological and hair loss therapies, including finasteride and dutasteride oral formulations for androgenetic alopecia, topical minoxidil solutions, atopic dermatitis treatments, and specialized scalp care products; anti-infective and antibacterial agents, including cephalosporin antibiotics, macrolides, and quinolone derivatives; urological medications, including treatments for benign prostatic hyperplasia and urinary tract conditions; respiratory and otolaryngological pharmaceuticals, such as antihistamines, antitussives, expectorants, and nasal decongestants; gastrointestinal agents, including proton pump inhibitors, mucosal protectants, and digestive regulators; musculoskeletal therapeutics, including non-steroidal anti-inflammatory drugs and muscle relaxants; and nutritional supplements, functional health foods, and medical derma-cosmetics. The company distributes its product offerings primarily to hospitals, medical clinics, and pharmacies across South Korea and selectively exports finished pharmaceuticals and active pharmaceutical ingredients to international markets. Founded in 1977 and headquartered in Gwacheon, South Korea, JW Shinyak Corp. operates as a key operating affiliate of JW Holdings Corporation and engages in biopharmaceutical research through its subsidiary JW Creagene Co., Ltd., which specializes in dendritic cell-based immunotherapies. In recent developments, the company has actively strengthened its leadership in dermatology and aesthetic medicine by expanding its portfolio of oral and topical hair loss treatments and advancing exclusive domestic marketing and distribution agreements for specialized dermatological and scalp care lines. Additionally, JW Shinyak Corp. consolidated its research and administrative functions into the JW Group Gwacheon R&D Center to accelerate formulation innovation, optimize specialized clinic-oriented commercial networks, and pursue strategic co-promotion alliances for next-generation specialty medications.